Cargando…

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy

The heterogeneity of tumor is considered as a major difficulty to victorious personalized cancer medicine. There is an extremeneed of consistent response evaluation for in vivo tumor heterogeneity anditscoupledconflict mechanisms. In this occasion researchers will be able to keep pace withpredictive...

Descripción completa

Detalles Bibliográficos
Autores principales: Khatami, Fatemeh, Tavangar, Seyed Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154523/
https://www.ncbi.nlm.nih.gov/pubmed/30288382
http://dx.doi.org/10.1007/s40200-018-0334-x
_version_ 1783357704183480320
author Khatami, Fatemeh
Tavangar, Seyed Mohammad
author_facet Khatami, Fatemeh
Tavangar, Seyed Mohammad
author_sort Khatami, Fatemeh
collection PubMed
description The heterogeneity of tumor is considered as a major difficulty to victorious personalized cancer medicine. There is an extremeneed of consistent response evaluation for in vivo tumor heterogeneity anditscoupledconflict mechanisms. In this occasion researchers will be able to keep pace withpredictive, preventive, personalized, and Participatory (P4) medicine for cancer managements. In fact tumor heterogeneity is a central part of cancer evolution,soin order to progress in understanding of the dynamics within a tumor some diagnostic apparatus should be improved. Latest molecular techniques like Next generation Sequencing (NGS) and ultra-deep sequencing could disclose some clones within a liquid tumor biopsy which mainly responsible of treatment resistance. Circulating tumor DNA (ctDNA) as a main component of liquid biopsy is agifted biomarker for cancer mutation tracking as well as profiling. Personalized medicine facilitate learning regarding to genetic pools of tumor and their possible respond to treatment which could be much easier by using of ctDNA.With this information, cliniciansarelooking forward to find the best strategies for prevention, screening, and treatment in the way of precision medicine. Currently, numerous clinical efficacy of such informative improved treatment are in hand. Here we represent the review of plasma-derived ctDNA studies use in personalized cancer managements.
format Online
Article
Text
id pubmed-6154523
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-61545232019-03-26 Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy Khatami, Fatemeh Tavangar, Seyed Mohammad J Diabetes Metab Disord Review Article The heterogeneity of tumor is considered as a major difficulty to victorious personalized cancer medicine. There is an extremeneed of consistent response evaluation for in vivo tumor heterogeneity anditscoupledconflict mechanisms. In this occasion researchers will be able to keep pace withpredictive, preventive, personalized, and Participatory (P4) medicine for cancer managements. In fact tumor heterogeneity is a central part of cancer evolution,soin order to progress in understanding of the dynamics within a tumor some diagnostic apparatus should be improved. Latest molecular techniques like Next generation Sequencing (NGS) and ultra-deep sequencing could disclose some clones within a liquid tumor biopsy which mainly responsible of treatment resistance. Circulating tumor DNA (ctDNA) as a main component of liquid biopsy is agifted biomarker for cancer mutation tracking as well as profiling. Personalized medicine facilitate learning regarding to genetic pools of tumor and their possible respond to treatment which could be much easier by using of ctDNA.With this information, cliniciansarelooking forward to find the best strategies for prevention, screening, and treatment in the way of precision medicine. Currently, numerous clinical efficacy of such informative improved treatment are in hand. Here we represent the review of plasma-derived ctDNA studies use in personalized cancer managements. Springer International Publishing 2018-03-26 /pmc/articles/PMC6154523/ /pubmed/30288382 http://dx.doi.org/10.1007/s40200-018-0334-x Text en © Springer International Publishing AG 2018
spellingShingle Review Article
Khatami, Fatemeh
Tavangar, Seyed Mohammad
Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
title Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
title_full Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
title_fullStr Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
title_full_unstemmed Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
title_short Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
title_sort circulating tumor dna (ctdna) in the era of personalized cancer therapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154523/
https://www.ncbi.nlm.nih.gov/pubmed/30288382
http://dx.doi.org/10.1007/s40200-018-0334-x
work_keys_str_mv AT khatamifatemeh circulatingtumordnactdnaintheeraofpersonalizedcancertherapy
AT tavangarseyedmohammad circulatingtumordnactdnaintheeraofpersonalizedcancertherapy